nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2010

microRNAs and lung cancer: tumors and 22-mers

verfasst von: Liqin Du, Alexander Pertsemlidis

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Work over the last decade has revealed novel regulatory mechanisms in pathological disease states that are mediated by microRNAs and has inspired researchers to begin elucidating the specific roles of miRNAs in the regulation of genes involved in cancer development and progression. Recently, miRNAs have been explored as therapeutic targets and diagnostic markers of cancer. In this paper, we review recent advances in the study of miRNAs involved in tumorigenesis, focusing on miRNA regulation of genes that have been demonstrated to play critical roles in lung cancer development. We discuss miRNA regulation of genes that play critical roles in the process of malignant transformation, angiogenesis and tumor metastasis, the dysregulation of miRNA expression in cancer development, and the development of miRNA-based diagnostics and therapeutics.

Yekta, S., Shih, I. H., & Bartel, D. P. (2004). MicroRNA-directed cleavage of HOXB8 mRNA. Science, 304, 594–596.PubMedCrossRef

Vasudevan, S., Tong, Y., & Steitz, J. A. (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science, 318, 1931–1934.PubMedCrossRef

Novotny, G. W., Sonne, S. B., Nielsen, J. E., Jonstrup, S. P., Hansen, M. A., Skakkebaek, N. E., et al. (2007). Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death and Differentiation, 14, 879–882.PubMedCrossRef

He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007). microRNAs join the p53 network—Another piece in the tumour-suppression puzzle. Nature Reviews Cancer, 7, 819–822.PubMedCrossRef

Cho, W. C. (2007). OncomiRs: The discovery and progress of microRNAs in cancers. Molecular Cancer, 6, 60.PubMedCrossRef

Hwang, H. W., & Mendell, J. T. (2006). MicroRNAs in cell proliferation, cell death, and tumorigenesis. British Journal of Cancer, 94, 776–780.PubMedCrossRef

Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6, 259–269.PubMedCrossRef

Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N., & Sauk, J. J. (2007). High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular Cancer, 6, 5.PubMedCrossRef

Lee, D. Y., Deng, Z., Wang, C. H., & Yang, B. B. (2007). MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proceedings of the National Academy of Sciences of the United States of America, 104, 20350–20355.PubMedCrossRef

10.

O’Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435, 839–843.PubMedCrossRef

11.

Mercatelli, N., Coppola, V., Bonci, D., Miele, F., Costantini, A., Guadagnoli, M., et al. (2008). The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE, 3, e4029.PubMedCrossRef

12.

Felicetti, F., Errico, M. C., Bottero, L., Segnalini, P., Stoppacciaro, A., Biffoni, M., et al. (2008). The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Research, 68, 2745–2754.PubMedCrossRef

13.

Wickramasinghe, N. S., Manavalan, T. T., Dougherty, S. M., Riggs, K. A., Li, Y., & Klinge, C. M. (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Research, 37, 2584–2595.PubMedCrossRef

14.

Yang, Y., Chaerkady, R., Beer, M. A., Mendell, J. T., & Pandey, A. (2009). Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics, 9, 1374–1384.PubMedCrossRef

15.

Si, M. L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y. Y. (2007). miR-21-mediated tumor growth. Oncogene, 26, 2799–2803.PubMedCrossRef

16.

Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189–198.PubMedCrossRef

17.

Taylor, D. D., & Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology, 110, 13–21.PubMedCrossRef

18.

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513–10518.PubMedCrossRef

19.

Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research, 18, 997–1006.PubMedCrossRef

20.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMedCrossRef

21.

Khosravi-Far, R., & Esposti, M. D. (2004). Death receptor signals to mitochondria. Cancer Biology and Therapy, 3, 1051–1057.PubMedCrossRef

22.

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., 3rd, & Hynes, N. E. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 100, 8933–8938.PubMedCrossRef

23.

Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S., & Benz, C. C. (2007). Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. Journal of Biological Chemistry, 282, 1479–1486.PubMedCrossRef

24.

Weiss, G. J., Bemis, L. T., Nakajima, E., Sugita, M., Birks, D. K., Robinson, W. A., et al. (2008). EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Annals of Oncology, 19, 1053–1059.PubMedCrossRef

25.

Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., & Leedman, P. J. (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. Journal of Biological Chemistry, 284, 5731–5741.PubMedCrossRef

26.

Eberhart, J. K., He, X., Swartz, M. E., Yan, Y. L., Song, H., Boling, T. C., et al. (2008). MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis. Nature Genetics, 40, 290–298.PubMedCrossRef

27.

La Rocca, G., Badin, M., Shi, B., Xu, S. Q., Deangelis, T., Sepp-Lorenzinoi, L., et al. (2009). Mechanism of growth inhibition by MicroRNA 145: The role of the IGF-I receptor signaling pathway. Journal of Cellular Physiology, 220, 485–491.PubMedCrossRef

28.

Bos, J. L. (1989). ras oncogenes in human cancer: A review. Cancer Research, 49, 4682–4689.PubMed

29.

Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer, 3, 11–22.PubMedCrossRef

30.

Zajac-Kaye, M. (2001). Myc oncogene: A key component in cell cycle regulation and its implication for lung cancer. Lung Cancer, 34(Suppl 2), S43–S46.PubMedCrossRef

31.

Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120, 635–647.PubMedCrossRef

32.

Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America, 105, 3903–3908.PubMedCrossRef

33.

Sampson, V. B., Rong, N. H., Han, J., Yang, Q., Aris, V., Soteropoulos, P., et al. (2007). MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Research, 67, 9762–9770.PubMedCrossRef

34.

Mayr, C., Hemann, M. T., & Bartel, D. P. (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315, 1576–1579.PubMedCrossRef

35.

Muntoni, A., & Reddel, R. R. (2005). The first molecular details of ALT in human tumor cells. Human Molecular Genetics, 14(Spec No. 2), R191–R196.PubMedCrossRef

36.

Mitomo, S., Maesawa, C., Ogasawara, S., Iwaya, T., Shibazaki, M., Yashima-Abo, A., et al. (2008). Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Science, 99, 280–286.PubMedCrossRef

37.

Gonzalo, S., Jaco, I., Fraga, M. F., Chen, T., Li, E., Esteller, M., et al. (2006). DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nature Cell Biology, 8, 416–424.PubMedCrossRef

38.

Benetti, R., Gonzalo, S., Jaco, I., Munoz, P., Gonzalez, S., Schoeftner, S., et al. (2008). A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nature Structural & Molecular Biology, 15, 268–279.CrossRef

39.

Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 104, 15805–15810.PubMedCrossRef

40.

Hotchkiss, R. S., Strasser, A., McDunn, J. E., & Swanson, P. E. (2009). Cell death. New England Journal of Medicine, 361, 1570–1583.PubMedCrossRef

41.

Porkka, K. P., Pfeiffer, M. J., Waltering, K. K., Vessella, R. L., Tammela, T. L., & Visakorpi, T. (2007). MicroRNA expression profiling in prostate cancer. Cancer Research, 67, 6130–6135.PubMedCrossRef

42.

Bottoni, A., Piccin, D., Tagliati, F., Luchin, A., Zatelli, M. C., & degli Uberti, E. C. (2005). miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology, 204, 280–285.PubMedCrossRef

43.

Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102, 13944–13949.PubMedCrossRef

44.

Mott, J. L., Kobayashi, S., Bronk, S. F., & Gores, G. J. (2007). mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene, 26, 6133–6140.PubMedCrossRef

45.

Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., et al. (2005). A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New England Journal of Medicine, 353, 1793–1801.PubMedCrossRef

46.

Cummins, J. M., He, Y., Leary, R. J., Pagliarini, R., Diaz, L. A., Jr., Sjoblom, T., et al. (2006). The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 103, 3687–3692.PubMedCrossRef

47.

Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Research, 65, 6029–6033.PubMedCrossRef

48.

Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., et al. (2009). MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proceedings of the National Academy of Sciences of the United States of America, 106, 12085–12090.PubMedCrossRef

49.

Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., et al. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6, 1586–1593.PubMed

50.

Hermeking, H. (2010). The miR-34 family in cancer and apoptosis. Cell Death and Differentiation, 17, 193–199.PubMedCrossRef

51.

He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130–1134.PubMedCrossRef

52.

le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., et al. (2007). Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO Journal, 26, 3699–3708.PubMedCrossRef

53.

Gillies, J. K., & Lorimer, I. A. (2007). Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle, 6, 2005–2009.PubMed

54.

Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G. V., Ciafre, S. A., et al. (2007). miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. Journal of Biological Chemistry, 282, 23716–23724.PubMedCrossRef

55.

Whang-Peng, J., Kao-Shan, C. S., Lee, E. C., Bunn, P. A., Carney, D. N., Gazdar, A. F., et al. (1982). Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science, 215, 181–182.PubMedCrossRef

56.

Zabarovsky, E. R., Lerman, M. I., & Minna, J. D. (2002). Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene, 21, 6915–6935.PubMedCrossRef

57.

Lerman, M. I., & Minna, J. D. (2000). The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Research, 60, 6116–6133.PubMed

58.

Ji, L., Nishizaki, M., Gao, B., Burbee, D., Kondo, M., Kamibayashi, C., et al. (2002). Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Research, 62, 2715–2720.PubMed

59.

Du, L., Schageman, J. J., Subauste, M. C., Saber, B., Hammond, S. M., Prudkin, L., et al. (2009). miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Molecular Cancer Research, 7, 1234–1243.PubMedCrossRef

60.

Prudkin, L., Behrens, C., Liu, D. D., Zhou, X., Ozburn, N. C., Bekele, B. N., et al. (2008). Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clinical Cancer Research, 14, 41–47.PubMedCrossRef

61.

Kondo, M., Ji, L., Kamibayashi, C., Tomizawa, Y., Randle, D., Sekido, Y., et al. (2001). Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene, 20, 6258–6262.PubMedCrossRef

62.

Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353–364.PubMedCrossRef

63.

Horn, L., & Sandler, A. B. (2009). Angiogenesis in the treatment of non-small cell lung cancer. The Proceedings of the American Thoracic Society, 6, 206–217.CrossRef

64.

Kerbel, R. S. (2008). Tumor angiogenesis. New England Journal of Medicine, 358, 2039–2049.PubMedCrossRef

65.

Yang, W. J., Yang, D. D., Na, S., Sandusky, G. E., Zhang, Q., & Zhao, G. (2005). Dicer is required for embryonic angiogenesis during mouse development. Journal of Biological Chemistry, 280, 9330–9335.PubMedCrossRef

66.

Bernstein, E., Kim, S. Y., Carmell, M. A., Murchison, E. P., Alcorn, H., Li, M. Z., et al. (2003). Dicer is essential for mouse development. Nature Genetics, 35, 215–217.PubMedCrossRef

67.

Suarez, Y., Fernandez-Hernando, C., Pober, J. S., & Sessa, W. C. (2007). Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circulation Research, 100, 1164–1173.PubMedCrossRef

68.

Kuehbacher, A., Urbich, C., Zeiher, A. M., & Dimmeler, S. (2007). Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circulation Research, 101, 59–68.PubMedCrossRef

69.

Suarez, Y., Fernandez-Hernando, C., Yu, J., Gerber, S. A., Harrison, K. D., Pober, J. S., et al. (2008). Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 105, 14082–14087.PubMedCrossRef

70.

Otsuka, M., Zheng, M., Hayashi, M., Lee, J. D., Yoshino, O., Lin, S., et al. (2008). Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. Journal of Clinical Investigation, 118, 1944–1954.PubMedCrossRef

71.

Shilo, S., Roy, S., Khanna, S., & Sen, C. K. (2008). Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 471–477.PubMedCrossRef

72.

Fish, J. E., Santoro, M. M., Morton, S. U., Yu, S., Yeh, R. F., Wythe, J. D., et al. (2008). miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell, 15, 272–284.PubMedCrossRef

73.

Wang, S., Aurora, A. B., Johnson, B. A., Qi, X., McAnally, J., Hill, J. A., et al. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell, 15, 261–271.PubMedCrossRef

74.

Kuhnert, F., Mancuso, M. R., Hampton, J., Stankunas, K., Asano, T., Chen, C. Z., et al. (2008). Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development, 135, 3989–3993.PubMedCrossRef

75.

Liu, B., Peng, X. C., Zheng, X. L., Wang, J., & Qin, Y. W. (2009). MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer, 66, 169–175.PubMedCrossRef

76.

Fish, J. E., & Srivastava, D. (2009). MicroRNAs: Opening a new vein in angiogenesis research. Science Signaling, 2, pe1.PubMedCrossRef

77.

Hua, Z., Lv, Q., Ye, W., Wong, C. K., Cai, G., Gu, D., et al. (2006). MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE, 1, e116.PubMedCrossRef

78.

Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genetics, 38, 1060–1065.PubMedCrossRef

79.

Poliseno, L., Tuccoli, A., Mariani, L., Evangelista, M., Citti, L., Woods, K., et al. (2006). MicroRNAs modulate the angiogenic properties of HUVECs. Blood, 108, 3068–3071.PubMedCrossRef

80.

Ruan, K., Fang, X., & Ouyang, G. (2009). MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Letters, 285, 116–126.PubMedCrossRef

81.

Chen, Y., & Gorski, D. H. (2008). Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111, 1217–1226.PubMedCrossRef

82.

Hurst, D. R., Edmonds, M. D., & Welch, D. R. (2009). Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Research, 69, 7495–7498.PubMedCrossRef

83.

Savagner, P., Kusewitt, D. F., Carver, E. A., Magnino, F., Choi, C., Gridley, T., et al. (2005). Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. Journal of Cellular Physiology, 202, 858–866.PubMedCrossRef

84.

Liu, Y. (2004). Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. Journal of the American Society of Nephrology, 15, 1–12.PubMedCrossRef

85.

Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2, 442–454.PubMedCrossRef

86.

Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682–688.PubMedCrossRef

87.

Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000). Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 406, 532–535.PubMedCrossRef

88.

Ma, L., & Weinberg, R. A. (2008). Micromanagers of malignancy: Role of microRNAs in regulating metastasis. Trends in Genetics, 24, 448–456.PubMedCrossRef

89.

Ciafre, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C. G., Sabatino, G., et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 334, 1351–1358.PubMedCrossRef

90.

Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., et al. (2007). MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA, 297, 1901–1908.PubMedCrossRef

91.

Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., et al. (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. Journal of Clinical Oncology, 24, 4677–4684.PubMedCrossRef

92.

Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., et al. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology, 10, 202–210.PubMedCrossRef

93.

Goodison, S., Urquidi, V., & Tarin, D. (1999). CD44 cell adhesion molecules. Molecular Pathology, 52, 189–196.PubMedCrossRef

94.

Park, S. M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development, 22, 894–907.PubMedCrossRef

95.

Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10, 593–601.PubMedCrossRef

96.

Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9, 582–589.PubMedCrossRef

97.

Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry, 283, 14910–14914.PubMedCrossRef

98.

Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. J., et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes and Development, 23, 2140–2151.PubMedCrossRef

99.

Tavazoie, S. F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147–152.PubMedCrossRef

100.

Crawford, M., Brawner, E., Batte, K., Yu, L., Hunter, M. G., Otterson, G. A., et al. (2008). MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochemical and Biophysical Research Communications, 373, 607–612.PubMedCrossRef

101.

Feller, S. M. (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene, 20, 6348–6371.PubMedCrossRef

102.

Kobashigawa, Y., Sakai, M., Naito, M., Yokochi, M., Kumeta, H., Makino, Y., et al. (2007). Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nature Structural & Molecular Biology, 14, 503–510.CrossRef

103.

Jansen, A. P., Camalier, C. E., & Colburn, N. H. (2005). Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Research, 65, 6034–6041.PubMedCrossRef

104.

Chen, Y., Knosel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., et al. (2003). Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. Journal of Pathology, 200, 640–646.PubMedCrossRef

105.

Mudduluru, G., Medved, F., Grobholz, R., Jost, C., Gruber, A., Leupold, J. H., et al. (2007). Loss of programmed cell death 4 expression marks adenoma–carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer, 110, 1697–1707.PubMedCrossRef

106.

Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., et al. (2009). An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene, 28, 73–84.PubMedCrossRef

107.

Lee, Y. S., & Dutta, A. (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes and Development, 21, 1025–1030.PubMedCrossRef

108.

Wang, Y., & Lee, C. G. (2009). MicroRNA and cancer—Focus on apoptosis. Journal of Cellular and Molecular Medicine, 13, 12–23.PubMedCrossRef

109.

Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., et al. (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research, 65, 9628–9632.PubMedCrossRef

110.

He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A microRNA polycistron as a potential human oncogene. Nature, 435, 828–833.PubMedCrossRef

111.

Mendell, J. T. (2008). miRiad roles for the miR-17-92 cluster in development and disease. Cell, 133, 217–222.PubMedCrossRef

112.

Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., et al. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 9, 405–414.PubMedCrossRef

113.

Sylvestre, Y., De Guire, V., Querido, E., Mukhopadhyay, U. K., Bourdeau, V., Major, F., et al. (2007). An E2F/miR-20a autoregulatory feedback loop. Journal of Biological Chemistry, 282, 2135–2143.PubMedCrossRef

114.

Bandi, N., Zbinden, S., Gugger, M., Arnold, M., Kocher, V., Hasan, L., et al. (2009). miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Research, 69, 5553–5559.PubMedCrossRef

115.

Chen, R. W., Bemis, L. T., Amato, C. M., Myint, H., Tran, H., Birks, D. K., et al. (2008). Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood, 112, 822–829.PubMedCrossRef

116.

Liu, Q., Fu, H., Sun, F., Zhang, H., Tie, Y., Zhu, J., et al. (2008). miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Research, 36, 5391–5404.PubMedCrossRef

117.

Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., et al. (2008). The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Medicine, 14, 1271–1277.PubMedCrossRef

118.

Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., et al. (2008). MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 27, 3845–3855.PubMedCrossRef

119.

Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. Journal of Biological Chemistry, 283, 1026–1033.PubMedCrossRef

120.

Lu, Z., Liu, M., Stribinskis, V., Klinge, C. M., Ramos, K. S., Colburn, N. H., et al. (2008). MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 27, 4373–4379.PubMedCrossRef

121.

Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6, 857–866.PubMedCrossRef

122.

Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425–436.PubMedCrossRef

123.

Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research, 64, 3753–3756.PubMedCrossRef

124.

Yu, S. L., Chen, H. Y., Chang, G. C., Chen, C. Y., Chen, H. W., Singh, S., et al. (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cells, 13, 48–57.CrossRef

125.

Wang, Q. Z., Xu, W., Habib, N., & Xu, R. (2009). Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Current Cancer Drug Targets, 9, 572–594.PubMedCrossRef

126.

Weidhaas, J. B., Babar, I., Nallur, S. M., Trang, P., Roush, S., Boehm, M., et al. (2007). MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Research, 67, 11111–11116.PubMedCrossRef

127.

Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., et al. (2009). MicroRNA expression, survival, and response to interferon in liver cancer. New England Journal of Medicine, 361, 1437–1447.PubMedCrossRef

128.

Ng, E. K., Chong, W. W., Jin, H., Lam, E. K., Shin, V. Y., Yu, J., et al. (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut, 58, 1375–1381.PubMedCrossRef

129.

Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal Haematology, 141, 672–675.CrossRef

130.

Lebanony, D., Benjamin, H., Gilad, S., Ezagouri, M., Dov, A., Ashkenazi, K., et al. (2009). Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. Journal of Clinical Oncology, 27, 2030–2037.PubMedCrossRef

131.

Liang, Y. (2008). An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics, 1, 61.PubMedCrossRef

132.

Pavlidis, N., & Fizazi, K. (2005). Cancer of unknown primary (CUP). Critical Reviews in Oncology/Hematology, 54, 243–250.PubMedCrossRef

133.

Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834–838.PubMedCrossRef

134.

Negrini, M., Nicoloso, M. S., & Calin, G. A. (2009). MicroRNAs and cancer—New paradigms in molecular oncology. Current Opinion in Cell Biology, 21, 470–479.PubMedCrossRef

135.

Wu, M., Jolicoeur, N., Li, Z., Zhang, L., Fortin, Y., L’Abbe, D., et al. (2008). Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis, 29, 1710–1716.PubMedCrossRef

136.

Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M., et al. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 105, 5166–5171.PubMedCrossRef

137.

Krutzfeldt, J., Kuwajima, S., Braich, R., Rajeev, K. G., Pena, J., Tuschl, T., et al. (2007). Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Research, 35, 2885–2892.PubMedCrossRef

138.

Fontana, L., Fiori, M. E., Albini, S., Cifaldi, L., Giovinazzi, S., Forloni, M., et al. (2008). Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE, 3, e2236.PubMedCrossRef

139.

Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896–899.PubMedCrossRef

140.

Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137, 1005–1017.PubMedCrossRef

141.

Zhu, S., Si, M. L., Wu, H., & Mo, Y. Y. (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). Journal of Biological Chemistry, 282, 14328–14336.PubMedCrossRef

142.

Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S. S., Ngankeu, A., et al. (2009). miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 16, 498–509.PubMedCrossRef

143.

Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Letters, 582, 1564–1568.PubMedCrossRef

144.

Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., et al. (2007). p53-Mediated activation of miRNA34 candidate tumor-suppressor genes. Current Biology, 17, 1298–1307.PubMedCrossRef

145.

Welch, C., Chen, Y., & Stallings, R. L. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26, 5017–5022.PubMedCrossRef

Titel: microRNAs and lung cancer: tumors and 22-mers
verfasst von: Liqin Du
Alexander Pertsemlidis
Publikationsdatum: 01.03.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9204-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

microRNAs and lung cancer: tumors and 22-mers

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

Lung cancer: From single-gene methylation to methylome profiling

Natural history of bronchial preinvasive lesions

Biography—Adi Gazdar

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie